Is CHA2DS2-VASc Score different between patients with and without atrial fibrillation suffering from peripheral arterial embolism?
Abstract
Objective:
CHA2DS2-VASc is a validated , straightforward and practical stratification of thromboembolic risk score for non-valvular atrial fibrillation (NVAF).
However it is usually used for stroke. In this trial we aim to compare the CHA2DS2-VASc
score between patients with and without AF suffering from peripheral arterial
embolism (PAE).
Materials and Methods:
We retrospectively evaluated the data registries of 150 patients who admitted
to hospital due to PAE between January 2011- December 2016. CHA2DS2-VASc score was
calculated for each patient
Results:
Atrial fibrillation was detected 59% of patients. Patients with AF were elder, more often
female gender, hypertension, heart failure, hyperlipidemia, stroke and
transient ischemic attack (p<0.05). The rate of prior PAE was similar between
two groups (p>0.05). Patients with AF had higher CHA2DS2-VASc
score then those without AF (5.1±1.7 vs 3.5±1.8 p<0.001). The rate of the patients with a CHA2DS2-VASc
score 1-3 was higher in non-AF group
(41% vs 23% p=0.017. However the rate of the patients with a CHA2DS2-VASc
score score 7-9 was higher in AF group (28% vs 6% p<0.001). In-hospital
mortality was similar between groups (14% vs 7% p=0.235).
Conclusion: Although AF patients had higher thromboembolic risk level based on CHA2DS2-VASc score. The rate of prior PAE rate was similar between AF and non-AF groups.
Keywords
References
- 1. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk ofstroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013; 44(5):1329–36.
- 2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8): 949–53
- 3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137 (2):263–72.
- 4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38) :2893-962.
- 5. Lip GYH and Edwards SJ, “Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis,” Thrombosis Research 2006; 118 (3) : 321–33
- 6. Lorentzen JE, Roder OC, Buchard Hansen HJ: Peripheral embolism. A follow-up of 130 consecutive patients submitted to embolectomy. Acta Chir Scand 1980; 502: 111–6.
- 7. Connett MC, Murray DH, Jr, Wenneker WW: Peripheral arterial emboli. Am J Surg 1984; 148 (1): 14–19.
- 8. Barretto PCA, Nobre MRC, Mansur AJ, Scipioni A, Ramires JA F: Peripheral Arterial Embolism. Report of Hospitalized Cases. Arq Bras Cardiol 2000; 74(4): 324–7.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Publication Date
June 1, 2018
Submission Date
April 17, 2017
Acceptance Date
August 16, 2017
Published in Issue
Year 2018 Volume: 25 Number: 2